Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans

Toxicology and Applied Pharmacology

Volumn 157, Issue 3, 1999, Pages 227-233

  Haley, Robert W ^a   Billecke, Scott ^b   La Du, Bert N ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Brain, drug effects; Butyrylcholinesterase; Chemical warfare agents; Epidemiology; Esterases, blood; Heterozygote; Homozygote; Human; Isoenzymes; Military personnel; Organophosphorus compounds; Paraoxonase; Persian Gulf syndrome; Polymorphism (genetics); Pyridostigmine bromide; Risk factors; Support, non U.S. gov't; Support, U.S. gov't, D.O.D.; Veterans

Indexed keywords

ALLOENZYME; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CHOLINESTERASE; DIMPYLATE; GLUTAMINE; INSECT REPELLENT; NERVE GAS; ORGANOPHOSPHATE PESTICIDE; PYRIDOSTIGMINE; SARIN; SOMAN;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FACTORIAL ANALYSIS; GENE ACTIVITY; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; RISK FACTOR; SOLDIER;

EID: 0033564496     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1999.8703     Document Type: Article

References (39)

1. Abou-Donia M. B., Wilmarth K. R., Abdel-Rahman A. A., Jensen K. F., Oehme F. W., Kurt T. L. Neurotoxicity resulting from coexposure to pyridostigmine bromide, DEET, and permethrin: Implications of Gulf War chemical exposures. Fundam. Appl. Toxicol. 34:1996a;201-222.
2. Abou-Donia M. B., Wilmarth K. R., Abdel-Rahman A. A., Jensen K. F., Oehme F. W., Kurt T. L. Increased neurotoxicity following concurrent exposure to pyridostigmine bromide, DEET, and chlorpyrifos. Fundam. Appl. Toxicol. 34:1996b;201-222.
3. Adkins S., Gan K. N., Mody M., La Du B. N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 52:1993;598-608.
4. Broomfield C. A., Ford K. W. Hydrolysis of nerve agents by plasma enzymes. Massoulie J. Cholinesterases. 1991;American Chemical Society, Washington.
5. Butler E. G., Eckerson H. W., La Du B. N. Paraoxon hydrolysis vs. covalent binding in the elimination of paraoxon in the rabbit. Drug Metab. Dispos. 15:1985;640-645.
6. Committee on Banking, Housing and Urban Affairs, U.S. Senate, 1994, US Chemical and Biological Warfare-Related Dual Use Exports to Iraq and Their Possible Impact on the Health Consequences of Persian Gulf War: Initial Findings and Recommendations for Immediate Action, National Academy Press, Washington, DC.
7. Costa L. G., McDonald B. E., Murphy S. D., Omenn G. S., Richter R. J., Motulsky A. G., Furlong C. E. Serum paraoxonase and its influence on paraoxon and chlorpyrifosoxon toxicity in rats. Toxicol. Appl. Pharmacol. 103:1990;66-76.
8. Davies H. G., Richter R. J., Keifer M., Broomfield C. A., Sowalla J., Furlong C. E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genet. 14:1996;334-336.
9. Fukuda K., Nisenbaum R., Stewart G., Thompson W. W., Robin L., Washko R. M., Noah D. L., Barrett D. H., Randall B., Herwaldt B. L., Mawle A. C., Reeves W. C. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. J. Am. Med. Assoc. 280:1998;981-988.
10. Furlong C. E., Richter R. J., Seidel S. L., Costa L. G., Motulsky A. G. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal. Biochem. 180:1989;242-247.
11. Geldmacher-von M. M., Diepgen T. L. The human serum paraoxonase-polymorphism and specificity. Toxicol. Environ. Chem. 18:1998;79-196.
12. Haley R. W. Replication of Gulf War syndromes. J. Am. Med. Assoc. 281:1999.
13. Haley R. W., Kurt T. M., Hom J. Is there a Gulf War syndrome? Searching for syndromes by factor analysis of symptoms. J. Am. Med. Assoc. 277:1997a;215-222.
14. Haley R. W., Hom J., Roland P. S., Bryan W. W., Van Ness P. C., Bonte F. J., Devous M. D. Sr., Mathews D., Fleckenstein J. L., Wians F. H. Jr., Wolfe G. I., Kurt T. L. Evaluation of neurologic function in Gulf War veterans: A blinded case-control study. J. Am. Med. Assoc. 277:1997b;223-230.
15. Haley R. W., Kurt T. L. Self-reported exposure to neurotoxic chemical combinations in the Gulf War: A cross-sectional epidemiologic study. J. Am. Med. Assoc. 277:1997c;231-237.
16. Harris H., Whittaker M. Differential inhibition of human serum cholinesterase with fluoride. Nature. 191:1961;496-498.
17. Hom J., Haley R. W., Kurt T. L. Neuropsychological correlates of Gulf War syndrome. Arch. Clin. Neuropsychol. 12:1997;531-544.
18. Hosmer D. W. Jr., Lemeshow S. Applied Logistic Regression. 1989;John Wiley & Sons, Inc. New York.
19. Humbert R., Adler D. A., Disteche C. M., Hassett C., Omiecinski C. J., Furlong C. E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3:1993;73-76.
20. Husain K., Vijayaraghavan R., Pant S. C., Raza S. K., Pandey S. K. Delayed neurotoxic effect of sarin in mice after repeated inhalation exposure. J. Appl. Toxicol. 13:1993;143-145.
21. Husain K., Pant S. C., Raza S. K., Singh R., Das Gupta S. A comparative study of delayed neurotoxicity in hens following repeated administration of organophosphorus compounds. Ind. J. Physiol. Pharmacol. 39:1995;47-50.
22. J. Am. Med. Assoc. 277:1997;238-245.
23. Jensen F. S., Skovgaard L. T., Viby-Mogensen J. Identification of human plasma cholinesterase variants in 6,688 individuals using biochemical analysis. Acta Anaesthesiol. Scand. 39:1995;157-162.
24. Kalow W., Genest K. A method for the detection of atypical forms of human cholinesterase: Determination of dibucaine numbers. Can. J. Biochem. 35:1957;339-346.
25. Kalow W., Lindsay H. A. A comparison of optical and manometric methods for the assay of human serum cholinesterase. Can. J. Biochem. 33:1955;568-574.
26. Keeler J. R., Hurst C. G., Dunn M. A. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. J. Am. Med. Assoc. 266:1991;693-695.
27. Konda I., Yamamoto M. Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res. 806:1998;271-273.
28. La Du B. N., Eckerson H. W. Could the human paraoxonase polymorphism account for different responses to certain environmental chemicals? Genetic Variability in Responses to Chemical Exposure. 1984a;Cold Spring Harbor Laboratory, Long Island.
29. La Du B. N., Eckerson H. W. The polymorphic paraoxonase/arylesterase isozymes of human serum. Fed. Proc. 43:1984b;2338-2341.
30. Li W. F., Costa L. G., Furlong C. E. Serum paraoxonase status: A major factor in determining resistance to organophosphates. J. Toxicol. Environ. Health. 40:1993;337-346.
31. Li W. F., Furlong C. E., Costa L. G. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol. Lett. 76:1995;219-226.
32. Loewenstein-Lichtenstein Y., Schwarz M., Glick D., Norgaard-Pedersen B., Zakut H., Soreq H. Genetic predisposition to adverse consequences of anti-cholinesterases in 'atypical' BChE carriers. Nature Med. 1:1995;1082-1085.
33. Mackness B., Mackness M. I., Arrol S., Turkie W., Durrington P. N. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br. J. Pharmacol. 122:1997;265-268.
34. Mutch E., Blain P. G., Williams F. M. Interindividual variations in enzymes controlling organophosphate toxicity in man. Hum. Exp. Toxicol. 11:1992;109-116.
35. Reitan R. M., Wolfson D. The Halstead-Reitan Neuropsychology Test Battery: Theory and Clinical Interpretation. 1993;Neuropsychology Press, Tucson.
36. Ruiz J., Blanche H., James R. W., Garin M. C., Vaisse C., Charpentier G., Cohen N., Morabia A., Passa P., Froguel P. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346:1995;869-872.
37. Serrato M., Marian A. J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 96:1995;3005-3008.
38. Sharabi Y., Danon Y., Berkenstadt H., Almog S., Mimouni-Block A., Zisman A., Dani S., Atsmon J. Survey of symptoms following intake of pyridostigmine during the Persian Gulf War. Isr. J. Med. Sci. 27:1991;656-658.
39. Shih D. M., Gu L., Xia Y. R., Navab M., Li W. F., Hama S., Castellani L. W., Furlong C. E., Costa L. G., Fogelman A. M., Lusis A. J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394:1998;284-287.